Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1345 to 1347 of 1347 entries
Sorted by: Best Match Show Resources per page
EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

García-Martín A, Navarrete C, Garrido-Rodríguez M, Prados ME, Caprioglio D, Appendino G, Muñoz E.
PMID: 34385107
Biomed Pharmacother. 2021 Oct;142:112007. doi: 10.1016/j.biopha.2021.112007. Epub 2021 Aug 09.

Some cannabinoids showed anti-inflammatory and antifibrotic activities. EHP-101 is an oral lipidic formulation of the novel non-psychotropic cannabidiol aminoquinone VCE-004.8, which showed antifibrotic activity in murine models of systemic sclerosis induced by bleomycin. We herein examined the effect of...

Cite
García-Martín A, Navarrete C, Garrido-Rodríguez M, et al. EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice. Biomed Pharmacother. 2021;142:112007doi: 10.1016/j.biopha.2021.112007.
García-Martín, A., Navarrete, C., Garrido-Rodríguez, M., Prados, M. E., Caprioglio, D., Appendino, G., & Muñoz, E. (2021). EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 142112007. https://doi.org/10.1016/j.biopha.2021.112007
García-Martín, Adela, et al. "EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 142 (2021): 112007. doi: https://doi.org/10.1016/j.biopha.2021.112007
García-Martín A, Navarrete C, Garrido-Rodríguez M, Prados ME, Caprioglio D, Appendino G, Muñoz E. EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice. Biomed Pharmacother. 2021 Oct;142:112007. doi: 10.1016/j.biopha.2021.112007. Epub 2021 Aug 09. PMID: 34385107.
Copy Download .nbib Format: NLM
Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: Restoring autophagy in alveolar epithelial cells.

International immunopharmacology

Duan JX, Guan XX, Yang HH, Mei WX, Chen P, Tao JH, Li Q, Zhou Y.
PMID: 34634687
Int Immunopharmacol. 2021 Dec;101:108211. doi: 10.1016/j.intimp.2021.108211. Epub 2021 Oct 08.

Vasoactive intestinal peptide (VIP) is an intrapulmonary neuropeptide with multi-function, including anti-fibrosis. However, the exact role of VIP in pulmonary fibrosis has not been documented. Here, we investigated the protective effect of VIP against pulmonary fibrosis in a murine...

Cite
Duan JX, Guan XX, Yang HH, et al. Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: Restoring autophagy in alveolar epithelial cells. Int Immunopharmacol. 2021;101:108211doi: 10.1016/j.intimp.2021.108211.
Duan, J. X., Guan, X. X., Yang, H. H., Mei, W. X., Chen, P., Tao, J. H., Li, Q., & Zhou, Y. (2021). Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: Restoring autophagy in alveolar epithelial cells. International immunopharmacology, 101108211. https://doi.org/10.1016/j.intimp.2021.108211
Duan, Jia-Xi, et al. "Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: Restoring autophagy in alveolar epithelial cells." International immunopharmacology vol. 101 (2021): 108211. doi: https://doi.org/10.1016/j.intimp.2021.108211
Duan JX, Guan XX, Yang HH, Mei WX, Chen P, Tao JH, Li Q, Zhou Y. Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: Restoring autophagy in alveolar epithelial cells. Int Immunopharmacol. 2021 Dec;101:108211. doi: 10.1016/j.intimp.2021.108211. Epub 2021 Oct 08. PMID: 34634687.
Copy Download .nbib Format: NLM
Mesenchymal stromal cells attenuate alveolar type 2 cells senescence through regulating NAMPT-mediated NAD metabolism.

Stem cell research & therapy

Lai X, Huang S, Lin S, Pu L, Wang Y, Lin Y, Huang W, Wang Z.
PMID: 35012648
Stem Cell Res Ther. 2022 Jan 10;13(1):12. doi: 10.1186/s13287-021-02688-w.

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive deadly fibrotic lung disease with high prevalence and mortality worldwide. The therapeutic potential of mesenchymal stem cells (MSCs) in pulmonary fibrosis may be attributed to the strong paracrine, anti-inflammatory,...

Cite
Lai X, Huang S, Lin S, et al. Mesenchymal stromal cells attenuate alveolar type 2 cells senescence through regulating NAMPT-mediated NAD metabolism. Stem Cell Res Ther. 2022;13(1):12doi: 10.1186/s13287-021-02688-w.
Lai, X., Huang, S., Lin, S., Pu, L., Wang, Y., Lin, Y., Huang, W., & Wang, Z. (2022). Mesenchymal stromal cells attenuate alveolar type 2 cells senescence through regulating NAMPT-mediated NAD metabolism. Stem cell research & therapy, 13(1), 12. https://doi.org/10.1186/s13287-021-02688-w
Lai, Xiaofan, et al. "Mesenchymal stromal cells attenuate alveolar type 2 cells senescence through regulating NAMPT-mediated NAD metabolism." Stem cell research & therapy vol. 13,1 (2022): 12. doi: https://doi.org/10.1186/s13287-021-02688-w
Lai X, Huang S, Lin S, Pu L, Wang Y, Lin Y, Huang W, Wang Z. Mesenchymal stromal cells attenuate alveolar type 2 cells senescence through regulating NAMPT-mediated NAD metabolism. Stem Cell Res Ther. 2022 Jan 10;13(1):12. doi: 10.1186/s13287-021-02688-w. PMID: 35012648; PMCID: PMC8751376.
Copy Download .nbib Format: NLM
Showing 1345 to 1347 of 1347 entries